{"id":"https://openalex.org/W2589141964","doi":"https://doi.org/10.1200/jco.2011.29.15_suppl.3015","title":"Phase I study of the multikinase prodrug SF1126 in solid tumors and B-cell malignancies.","display_name":"Phase I study of the multikinase prodrug SF1126 in solid tumors and B-cell malignancies.","publication_year":2011,"publication_date":"2011-05-20","ids":{"openalex":"https://openalex.org/W2589141964","doi":"https://doi.org/10.1200/jco.2011.29.15_suppl.3015","mag":"2589141964"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2011.29.15_suppl.3015","doi":"https://doi.org/10.1200/jco.2011.29.15_suppl.3015","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2011.29.15_suppl.3015","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5101638085","display_name":"Daruka Mahadevan","orcid":"https://orcid.org/0000-0002-7129-5593","observed_orcids":["https://orcid.org/0000-0002-7129-5593"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"D. Mahadevan","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5019995834","display_name":"Elena Gabriela Chiorean","orcid":"https://orcid.org/0000-0003-3306-9592","observed_orcids":["https://orcid.org/0000-0003-3306-9592"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"E. G. Chiorean","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5036847798","display_name":"Wayne B. Harris","orcid":"https://orcid.org/0000-0001-8864-7228","observed_orcids":["https://orcid.org/0000-0001-8864-7228"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"W. Harris","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5080900202","display_name":"Daniel D. Von Hoff","orcid":"https://orcid.org/0000-0003-4723-7681","observed_orcids":["https://orcid.org/0000-0003-4723-7681"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"D. D. Von Hoff","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5063955723","display_name":"Anne Younger","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"A. Younger","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5044062732","display_name":"Diane Rensvold","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"D. M. Rensvold","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007376704","display_name":"Felina M. Cordova-Marks","orcid":"https://orcid.org/0000-0002-3317-5945","observed_orcids":["https://orcid.org/0000-0002-3317-5945"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"F. Cordova","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"W. Qi","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"W. Qi","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5047610724","display_name":"Candace Shelton","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"C. F. Shelton","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103990662","display_name":"Mark Becker","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"M. D. Becker","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046281810","display_name":"Joseph R. Garlich","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"J. R. Garlich","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5112223884","display_name":"R. K. Ramanathan","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"R. K. Ramanathan","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":10,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"29","issue":"15_suppl","first_page":"3015","last_page":"3015"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10952","display_name":"PI3K/AKT/mTOR signaling in cancer","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10952","display_name":"PI3K/AKT/mTOR signaling in cancer","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11235","display_name":"Statistical Methods in Clinical Trials","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2613","display_name":"Statistics and Probability"},"field":{"id":"https://openalex.org/fields/26","display_name":"Mathematics"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/ly294002","display_name":"LY294002","score":0.9900000095367432},{"id":"https://openalex.org/keywords/pi3k-mtor-inhibition","display_name":"PI3K/mTOR inhibition","score":0.8880000114440918},{"id":"https://openalex.org/keywords/solid-tumors","display_name":"solid tumors","score":0.7960000038146973},{"id":"https://openalex.org/keywords/b-cell-malignancies","display_name":"B-cell malignancies","score":0.9879999756813049},{"id":"https://openalex.org/keywords/chronic-lymphocytic-leukemia","display_name":"chronic lymphocytic leukemia","score":0.996999979019165},{"id":"https://openalex.org/keywords/diffuse-large-b-cell-lymphoma","display_name":"diffuse large B-cell lymphoma","score":0.9710000157356262},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.8450000286102295},{"id":"https://openalex.org/keywords/gastrointestinal-toxicity","display_name":"gastrointestinal toxicity","score":0.6990000009536743},{"id":"https://openalex.org/keywords/rituximab-combination","display_name":"rituximab combination","score":0.8220000267028809},{"id":"https://openalex.org/keywords/akt-phosphorylation","display_name":"Akt phosphorylation","score":0.7649999856948853}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8528482913970947},{"id":"https://openalex.org/C2776820818","wikidata":"https://www.wikidata.org/wiki/Q7699074","display_name":"Temsirolimus","level":5,"score":0.6312386989593506},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.5012180805206299},{"id":"https://openalex.org/C2780653079","wikidata":"https://www.wikidata.org/wiki/Q412323","display_name":"Rituximab","level":3,"score":0.487633615732193},{"id":"https://openalex.org/C2778245361","wikidata":"https://www.wikidata.org/wiki/Q409744","display_name":"Calicheamicin","level":3,"score":0.4726856052875519},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4706610441207886},{"id":"https://openalex.org/C108215921","wikidata":"https://www.wikidata.org/wiki/Q603741","display_name":"Prodrug","level":2,"score":0.45401209592819214},{"id":"https://openalex.org/C2778822529","wikidata":"https://www.wikidata.org/wiki/Q1951525","display_name":"Progressive disease","level":3,"score":0.4121936857700348},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.3933527171611786},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.3645787239074707},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3603195548057556},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3586605489253998},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.33183616399765015},{"id":"https://openalex.org/C86554907","wikidata":"https://www.wikidata.org/wiki/Q285613","display_name":"PI3K/AKT/mTOR pathway","level":3,"score":0.31126368045806885},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.28629666566848755},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.2794577181339264},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.10795554518699646},{"id":"https://openalex.org/C183713625","wikidata":"https://www.wikidata.org/wiki/Q5282002","display_name":"Discovery and development of mTOR inhibitors","level":4,"score":0.09059247374534607},{"id":"https://openalex.org/C190283241","wikidata":"https://www.wikidata.org/wiki/Q14599311","display_name":"Apoptosis","level":2,"score":0.0},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0},{"id":"https://openalex.org/C2778729363","wikidata":"https://www.wikidata.org/wiki/Q11688946","display_name":"Myeloid leukemia","level":2,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2011.29.15_suppl.3015","doi":"https://doi.org/10.1200/jco.2011.29.15_suppl.3015","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2011.29.15_suppl.3015","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2023041438","https://openalex.org/W2556090196","https://openalex.org/W2241003473","https://openalex.org/W2506878738","https://openalex.org/W2318637030","https://openalex.org/W2033791227","https://openalex.org/W4241124341","https://openalex.org/W2555159995","https://openalex.org/W2550966673","https://openalex.org/W2467145449"],"abstract_inverted_index":{"3015":[0],"Background:":[1],"SF1126":[2,80,204,236,238,267,286],"is":[3,24,287,322],"a":[4,11,31,76,129,243],"peptidic":[5],"prodrug":[6],"that":[7,17,266],"converts":[8],"to":[9,26,34,107,118,125,242,293],"LY294002,":[10],"widely":[12],"studied":[13],"dual":[14],"PI3K/mTOR":[15],"inhibitor":[16],"historically":[18],"suffered":[19],"from":[20],"poor":[21],"solubility.":[22],"LY294002":[23,44],"conjugated":[25],"an":[27],"RGD":[28],"peptide":[29],"via":[30],"cleavable":[32],"linker":[33],"form":[35],"SF1126,":[36],"which":[37],"demonstrates":[38],"improved":[39],"solubility":[40],"and":[41,54,56,128,185,215,254,259,274,302,325,337,351],"site":[42],"selectivity.":[43],"also":[45],"inhibits":[46],"other":[47],"cancer":[48,61],"target":[49],"kinases":[50],"including":[51],"DNA-PK,":[52],"PIM1,":[53],"PLK1":[55],"induces":[57],"oxidative":[58],"stress":[59],"in":[60,72,75,92,164,179,307,340,352],"cells.":[62],"Methods:":[63],"39":[64],"pts":[65,109,214],"with":[66,110,145,246,354],"advanced":[67],"solid":[68,309,341],"tumors":[69],"were":[70,124,141],"enrolled":[71],"sequential":[73],"cohorts":[74],"standard":[77,119],"3+3":[78],"design.":[79],"was":[81,105,115,160,177,313,326,356],"administered":[82,98],"days":[83],"1,":[84],"4":[85,93],"weekly":[86,301],"by":[87,297],"90":[88],"min":[89],"i.v.":[90,298],"infusion":[91,299],"wk":[94],"cycles.":[95],"The":[96,316],"maximum":[97],"dose":[99,155,318],"(MAD)":[100],"level":[101],"cohort":[102],"(1,110":[103],"mg/m2)":[104],"expanded":[106],"allow":[108],"B-cell":[111,345],"malignancies.":[112],"Clinical":[113],"response":[114,163,245],"evaluated":[116],"according":[117],"disease-specific":[120],"criteria.":[121],"Primary":[122],"objectives":[123],"determine":[126],"safety":[127],"recommended":[130],"phase":[131],"2":[132,209],"(RP2)":[133],"dose.":[134],"Results:":[135],"Part":[136,208],"1":[137,147,175,216],"Solid":[138],"Tumors.":[139],"Toxicities":[140],"generally":[142],"grade":[143],"1/2":[144],"only":[146],"DLT":[148],"(transient":[149],"G3":[150],"diarrhea":[151],"at":[152,290],"180":[153],"mg/m2":[154,295,321],"level).":[156],"Stable":[157],"disease":[158,305],"(SD)":[159],"the":[161,323,330],"best":[162],"19":[165],"of":[166,169,201,203,235,262,270,281,319,332],"33":[167],"(58%)":[168],"evaluable":[170],"pts.":[171,311,343],"Prolonged":[172],"SD":[173,231],"over":[174,272],"yr":[176],"noted":[178],"one":[180,186],"GIST":[181],"pt":[182,190,218,224],"(18":[183],"cycles)":[184,192],"renal":[187],"cell":[188],"carcinoma":[189],"(21":[191],"who":[193,225],"had":[194,226],"progressed":[195,227],"on":[196,205,228,329],"temsirolimus":[197],"representing":[198],"possible":[199],"evidence":[200],"effect":[202],"mTORC1":[206],"resistance.":[207],"B-Cell":[210],"Malignancies.":[211],"Four":[212],"CLL":[213,223,263],"DLBCL":[217],"have":[219],"been":[220],"treated.":[221],"One":[222],"rituximab":[229,240,355],"achieved":[230],"after":[232],"two":[233],"months":[234],"alone.":[237],"plus":[239],"led":[241],"partial":[244],"decreased":[247],"absolute":[248],"lymphocyte":[249],"count,":[250],"lesion":[251],"sum":[252],"products":[253],"spleen":[255],"size.":[256],"Flow":[257],"cytometry":[258],"Western":[260],"blotting":[261],"cells":[264],"showed":[265,303],"reduced":[268],"expression":[269],"p-AKT":[271],"time":[273],"increased":[275],"late":[276],"apoptosis":[277],"demonstrating":[278],"pharmacodynamic":[279],"inhibition":[280],"activated":[282],"PI3K":[283],"signaling.":[284],"Conclusions:":[285],"well":[288],"tolerated":[289],"doses":[291],"up":[292],"1,110":[294,320],"given":[296],"twice":[300],"significant":[304],"stabilization":[306],"multiple":[308],"tumor":[310,342],"MTD":[312],"not":[314],"reached.":[315],"RP2":[317],"MAD":[324],"reached":[327],"based":[328],"findings":[331],"safety,":[333],"PK,":[334],"PD,":[335],"toxicity,":[336],"activity":[338,349],"profile":[339],"In":[344],"malignancies":[346],"promising":[347],"preliminary":[348],"alone":[350],"concert":[353],"noted.":[357]},"counts_by_year":[{"year":2024,"cited_by_count":1},{"year":2022,"cited_by_count":1},{"year":2020,"cited_by_count":1},{"year":2015,"cited_by_count":1},{"year":2013,"cited_by_count":3},{"year":2012,"cited_by_count":2}],"updated_date":"2026-09-27T08:07:27.782135","created_date":"2017-03-03T00:00:00"}